These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 29948107)

  • 1. Radioembolization with
    Ho CL; Chen S; Cheung SK; Leung YL; Cheng KC; Wong KN; Wong YH; Leung TWT
    Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2110-2121. PubMed ID: 29948107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partition Model-Based 99mTc-MAA SPECT/CT Predictive Dosimetry Compared with 90Y TOF PET/CT Posttreatment Dosimetry in Radioembolization of Hepatocellular Carcinoma: A Quantitative Agreement Comparison.
    Gnesin S; Canetti L; Adib S; Cherbuin N; Silva Monteiro M; Bize P; Denys A; Prior JO; Baechler S; Boubaker A
    J Nucl Med; 2016 Nov; 57(11):1672-1678. PubMed ID: 27307346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results.
    Garin E; Lenoir L; Rolland Y; Edeline J; Mesbah H; Laffont S; Porée P; Clément B; Raoul JL; Boucher E
    J Nucl Med; 2012 Feb; 53(2):255-63. PubMed ID: 22302962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis.
    Garin E; Rolland Y; Edeline J; Icard N; Lenoir L; Laffont S; Mesbah H; Breton M; Sulpice L; Boudjema K; Rohou T; Raoul JL; Clement B; Boucher E
    J Nucl Med; 2015 Mar; 56(3):339-46. PubMed ID: 25678490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioembolization of hepatocarcinoma with (90)Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology.
    Chiesa C; Mira M; Maccauro M; Spreafico C; Romito R; Morosi C; Camerini T; Carrara M; Pellizzari S; Negri A; Aliberti G; Sposito C; Bhoori S; Facciorusso A; Civelli E; Lanocita R; Padovano B; Migliorisi M; De Nile MC; Seregni E; Marchianò A; Crippa F; Mazzaferro V
    Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1718-1738. PubMed ID: 26112387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of Technetium-99m Macroaggregated Albumin and Yttrium-90 Glass Microsphere Biodistribution in Hepatocellular Carcinoma: A Retrospective Review of Pretreatment Single Photon Emission CT and Posttreatment Positron Emission Tomography/CT.
    Haste P; Tann M; Persohn S; LaRoche T; Aaron V; Mauxion T; Chauhan N; Dreher MR; Johnson MS
    J Vasc Interv Radiol; 2017 May; 28(5):722-730.e1. PubMed ID: 28238581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
    Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significant Value of
    Ho CL; Chen S; Cheung SK; Leung TWT
    PET Clin; 2019 Oct; 14(4):459-467. PubMed ID: 31472743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept.
    Garin E; Lenoir L; Edeline J; Laffont S; Mesbah H; Porée P; Sulpice L; Boudjema K; Mesbah M; Guillygomarc'h A; Quehen E; Pracht M; Raoul JL; Clement B; Rolland Y; Boucher E
    Eur J Nucl Med Mol Imaging; 2013 Jul; 40(7):1057-68. PubMed ID: 23613103
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Jreige M; Mitsakis P; Van Der Gucht A; Pomoni A; Silva-Monteiro M; Gnesin S; Boubaker A; Nicod-Lalonde M; Duran R; Prior JO; Denys A; Schaefer N
    Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1215-1222. PubMed ID: 28233086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative dosimetry between
    Jadoul A; Bernard C; Lovinfosse P; Gérard L; Lilet H; Cornet O; Hustinx R
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):828-837. PubMed ID: 31388721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility of imaging
    Kunnen B; Dietze MMA; Braat AJAT; Lam MGEH; Viergever MA; de Jong HWAM
    Med Phys; 2020 Mar; 47(3):1105-1114. PubMed ID: 31855282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres.
    Garin E; Rolland Y; Laffont S; Edeline J
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):559-75. PubMed ID: 26338177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET-CT post therapy dosimetry in radioembolization with resin
    Richetta E; Pasquino M; Poli M; Cutaia C; Valero C; Tabone M; Paradisi BP; Pacilio M; Pellerito RE; Stasi M
    Phys Med; 2019 Aug; 64():16-23. PubMed ID: 31515015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modeling for safe and effective 90Y radioembolization.
    Kao YH; Hock Tan AE; Burgmans MC; Irani FG; Khoo LS; Gong Lo RH; Tay KH; Tan BS; Hoe Chow PK; Eng Ng DC; Whatt Goh AS
    J Nucl Med; 2012 Apr; 53(4):559-66. PubMed ID: 22343503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High quality imaging and dosimetry for yttrium-90 (
    Duan H; Khalaf MH; Ferri V; Baratto L; Srinivas SM; Sze DY; Iagaru A
    Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2426-2436. PubMed ID: 33443618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with
    Garin E; Rolland Y; Pracht M; Le Sourd S; Laffont S; Mesbah H; Haumont LA; Lenoir L; Rohou T; Brun V; Edeline J
    Liver Int; 2017 Jan; 37(1):101-110. PubMed ID: 27514012
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Tabotta F; Gnesin S; Dunet V; Ponti A; Digklia A; Boughdad S; Schaefer N; Prior JO; Villard N; Tsoumakidou G; Denys A; Duran R
    Sci Rep; 2023 Aug; 13(1):13118. PubMed ID: 37573346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total Lesion Glycolysis on 18F-FDG PET/CT Is a Better Prognostic Factor Than Tumor Dose on 90Y PET/CT in Patients With Hepatocellular Carcinoma Treated With 90Y Transarterial Radioembolization.
    Hwang SH; Hong HS; Kim D; Kim GM; Lee HW; Lee M; Kim DY; Park MA; Yun M
    Clin Nucl Med; 2022 Jun; 47(6):e437-e443. PubMed ID: 35384891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of dose-volume histograms for metabolic response prediction in hepatocellular carcinoma patients undergoing transarterial radioembolization with Y-90 resin microspheres.
    Coskun N; Kartal MO; Kartal AS; Cayhan V; Ozdemir M; Canyigit M; Ozdemir E
    Ann Nucl Med; 2024 Jul; 38(7):525-533. PubMed ID: 38647875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.